Biocon Q4 FY26: Biosimilars Lead, Integration Done, Deleveraging Becomes the Priority

Biocon ended Q4 FY26 with consolidated total income of INR 4,569 crore and revenue from operations of INR 4,517 crore. The company described FY26 as an inflection point, highlighting that it has moved from an investment-heavy phase to an execution phase.

The quarter’s growth was led by biosimilars. Biosimilars revenue in Q4 FY26 was INR 2,756 crore, up 12% year-on-year. Generics revenue was INR 847 crore, and management noted it grew 13% year-on-year after excluding one-time generic lenalidomide sales in Q4 FY25. CRDMO (Syngene) revenue was INR 1,037 crore, up 2% year-on-year.

Consolidated EBITDA for Q4 FY26 was INR 1,073 crore with a margin of 23%. Net profit before exceptional items was INR 179 crore. For the full year, total income was INR 17,270 crore and revenue from operations was INR 16,927 crore. EBITDA was INR 3,798 crore with a margin of 22%, and net profit before exceptional items was INR 436 crore.

The shift to a unified biopharma structure

Management emphasised that the integration of the biosimilars business into Biocon has been completed, creating “one unified global biopharma platform.” The chairperson highlighted that the integration was completed in under 100 days with no disruption to business operations.

The company linked this simplification to better capital allocation, operating discipline, and synergy across supply chain and commercial execution. The commentary also repeated that the “major investment phase is substantially complete,” and the emphasis will shift toward improving utilisation and margins.

Segment performance: biosimilars drive profitability

Biosimilars remained the core contributor. The segment delivered Q4 FY26 EBITDA of INR 720 crore, up 33% year-on-year, with an EBITDA margin of 26%. For FY26, biosimilars revenue was INR 10,431 crore, up 16% year-on-year, while EBITDA was reported at INR 2,751 crore with a 26% margin.

Management highlighted activity across major regions:

North America: improving access and uptake across the base portfolio, and continued traction for Yesintek.

Europe: stable performance in a tender-led environment, and continued expansion in oncology, immunology, and ophthalmology.

Emerging markets: steady, access-led growth supported by tenders and selective launches.

The company also discussed product approvals and launches including denosumab biosimilars. In the transcript, management referred to Bosaya and Aukelso as their U.S. denosumab biosimilars. They also mentioned European expansion of denosumab under the brand Evfraxy.

Financial summary

Metric (INR crore)	Q4 FY26	FY26
Revenue from operations	4,517	16,927
Total income	4,569	17,270
EBITDA	1,073	3,798
EBITDA margin	23%	22%
Net profit (before exceptional items)	179	436
Biosimilars revenue	2,756	10,431
Generics revenue	847	3,168
CRDMO revenue	1,037	3,739

Generics: profitability rebuilding after capex

Generics revenue was broadly stable quarter-on-quarter at INR 847 crore in Q4 FY26 versus INR 851 crore in Q3 FY26. The quarter’s key takeaway was margin improvement. Generics EBITDA was INR 75 crore in Q4 FY26, with an EBITDA margin of 8%, improving by nearly 300 basis points sequentially.

Management noted that margins are still weighed down by higher costs from recently commissioned facilities, and they expect a gradual rebuild as utilisation improves.

On product momentum, management referenced approvals for liraglutide across the U.S. and other markets during FY26. This is positioned as part of Biocon’s broader GLP-1 and metabolic disease franchise.

CRDMO (Syngene): steady revenue, margin pressure

Syngene’s revenue from operations grew 3% year-on-year for FY26, while Q4 FY26 revenue grew 2% year-on-year and 13% sequentially. Segment EBITDA margin for the year was discussed as being in line with Syngene’s revised guidance, at about 25%.

Management also acknowledged that FY26 performance was impacted by a single large-molecule biologics client, though they said the underlying business showed steady momentum.

On the strategic front, Syngene’s platform expansion included an ADC discovery laboratory and a commissioned GMP bioconjugation suite, intended to enable end-to-end ADC capabilities.

Balance sheet focus: debt reduction and interest savings

One of the more concrete takeaways from the earnings call Q&A was the stance on deleveraging. The CFO stated that every dollar of free cash flow generated will first be used to reduce debt. He said net debt reduced from over USD 1.5 billion in March 2025 to about USD 1.1 billion, and is expected to hover between USD 1.1 to 1.2 billion depending on working capital movements.

The management also pointed to interest cost reduction. The CFO indicated interest costs have fallen from around INR 280 to 300 crore per quarter earlier to roughly INR 210 to 220 crore per quarter now. The company expects the full annualised interest savings benefit to be visible from FY27.

What to watch in FY27

Biocon did not provide formal numeric guidance for FY27 and FY28, but management commentary provided a directional roadmap.

Biosimilars scale-up is expected to strengthen progressively through FY27, with incremental impact from new launches skewing toward the second half.

Malaysia manufacturing expansion remains a key capacity lever. The CFO said drug product line 2 is being qualified and should become operational soon, and the drug substance doubling is expected towards the end of FY27.

Management also reiterated that they do not see a need for major greenfield capex at this stage, and only minor debottlenecking may be required.

Closing takeaways

Biocon’s FY26 narrative is built around three themes: completion of integration, biosimilars-led growth with improving profitability, and a renewed focus on capital discipline and deleveraging.

The numbers show that biosimilars are now carrying both growth and margin improvement. Generics is in the middle of a utilisation-led profitability rebuild, and Syngene is working through client concentration impact while continuing to invest in new modalities.

With the company now publicly anchoring free cash flow toward debt reduction and with interest cost savings already visible, FY27 will largely be judged on whether this execution phase translates into sustained margin expansion and improved returns on capital employed.